Couple of open access articles on the rationale of clearing target proteins from the CSF in neurodegenerative diseases

Parkinson's disease
Menéndez-González M, Padilla-Zambrano HS, Tomás-Zapico C, García BF. Clearing Extracellular Alpha-Synuclein from Cerebrospinal Fluid: A New Therapeutic Strategy in Parkinson's Disease. Brain Sci. 2018 Mar 23;8(4). pii: E52. doi: 10.3390/brainsci8040052
 Effects of intracellular and extracellular alpha-synuclein.

Alzheimer's disease
Menendez-Gonzalez M, Padilla-Zambrano HS, Alvarez G, Capetillo-Zarate E, Tomas-Zapico C and Costa A (2018) Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer’s Disease. Front. Aging Neurosci. 10:100. doi: 10.3389/fnagi.2018.00100
Graph representing the evolution of Aβ in the different pools. On the left, evolution of Aβ levels across the different stages of a AD. On the right, predicted evolution of Aβ levels in a case of AD treated at presymptomatic stage. islSF, insoluble pool in the ISF; slSF, soluble pool in the ISF.